Please login to the form below

Not currently logged in
Email:
Password:

Nycomed reports increased Q1 earnings

Nycomed has posted a 38 per cent increase in pre-tax earnings to €294.4m in the first quarter of 2011, boosted by a one off-payment of €131.1m from its marketing partner Forest Laboratories following the US approval of Daliresp

Nycomed has posted a 38 per cent increase in pre-tax earnings to €294.4m in the first quarter of 2011. This figure was boosted by a one off-payment of €131.1m from its marketing partner Forest Laboratories following the US approval of COPD drug Daliresp (roflumilast).

Its revenues increased by 15 per cent in local currencies, it said, but did not reveal the amount.

The company emphasised progress in the three leading emerging regions, with Russia/CIS registering growth of 34.9 per cent to €139.5m; Latin America growing by almost 25 per cent to €106m; Asia Pacific/Middle East and Africa up by 72 per cent to €91.8m.

Nycomed chief executive Håkan Björklund said: "Continued strong expansion in these younger markets, which we believe will be an engine for growth in our industry, helped to offset declines in Western Europe and the US, with Russia/CIS now our second-largest region after Europe, and Asia Pacific, Middle East overtaking North America in overall sales."

He added: "We believe the anticipated acquisition of Nycomed by Takeda Pharmaceutical Company Limited, announced last week, will bring together Takeda's track record of innovation and Nycomed's efficient commercialisation and manufacturing infrastructure to create a global player able to meet the needs of patients and healthcare providers around the world."

26th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics